SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the
Company")
Conversion Notice and Total Voting
Rights
9 February 2024 -
SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life
science business focused on skin health, announces that it received
a Conversion Notice on 5 February 2024 from Macquarie
("Macquarie") for £50,000 of Convertible Bonds from the £5.0
million convertible bond facility announced on 25 January 2024. The
Company has drawn a total of £1,600,000 under the
Facility.
This notice is for a pilot
conversion to ensure smooth facilitation of the process.
SkinBioTherapeutics will issue
487,659 ordinary shares of £0.01 per share ("Ordinary Shares") at a
conversion price of 10.25p per Ordinary Share.
Admission and Total Voting
Rights
Application will be made for
the 487,659 new ordinary shares, which will
rank pari passu in all respects with the existing
ordinary shares of the Company, to be admitted to AIM, which is
expected to occur on or around 8.00 a.m. on 13 February 2024
("Admission"). Upon Admission, the total number of issued shares
and the total number of voting rights in the Company will be
190,850,600.
The above figure of 190,850,600
should be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
-Ends-
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
|
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
Tel:
+44 (0) 191 495 7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
Tel:
+44 (0) 20 7220 0500
|
|
Instinctif Partners (financial press)
Melanie Toyne-Sewell / Jack
Kincade
|
Tel:
+44 (0) 20 7457 2020
SkinBioTherapeutics@instinctif.com
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life
science company focused on skin health. The Company's proprietary
platform technology, SkinBiotix®, is based upon discoveries made by
Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of
skin healthcare sectors, the most advanced of which are cosmetic
skincare and food supplements to modulate the immune system by
harnessing the gut-skin axis. In each area SkinBioTherapeutics
plans to exemplify its technology through human studies. The
Company's first product, AxisBiotix-Ps™, a food supplement to
address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April
2017 and is based in Newcastle, UK. For more information,
visit: www.skinbiotherapeutics.com and
www.axisbiotix.com.
|